Partnership introduced antimicrobial eye dropper at Pharmapack
Activated Rispharm, the multidose antimicrobial dropper to help prevent eye microbial infections for patients, was introduced at Pharmapack 2022 (18th & 19th May in Paris).
Developed in a strategic commercial partnership between Berry Global, provider of innovative packaging and engineered products, and Pylote, focused in the industrial mineral chemistry, the solution was presented on the Berry Global stand. Activated Rispharm was also submitted into the 2022 Pharmapack Awards and was seen at the exhibition’s Innovation Gallery.
Activated Rispharm is a multidose eye dropper with nozzle and cap activated to kill bacteria and viruses continuously to deliver hygienic doses at each use and, thus, to reduce infection risks. The product delivers antimicrobial protection properties resulting from the combination of Pylote’s expertise in mineral chemistry that helps protect patients/users from the risk of microbial infections, with Berry Global’s expertise in sustainable healthcare packaging.
Pylote’s patented mineral technology – microspheres – is embedded into the resin masterbatch, and is fully recyclable, thus supporting efforts towards sustainability.
Activated Rispharm offers significant benefits including:
- Proven and certified antimicrobial mineral protection of dropper tip where over 85% of the contamination of the drops is found according to clinical study
- Proven and certified effectiveness against Adenovirus type 3 (conjunctivitis), Escherichia Coli and Staphylococcus aureus.
- Allows patients to have hygienic applications for every use with a multidose dropper.
- Reduces the amount of plastic waste by 16 times for one month treatment compared to monodose solutions.
- No change in patient treatment methods.
- Fully compliant, stable and biocompatible while certified non-irritant and non-cytotoxic technology (ISO10993:2010)
- No modifications required to packaging design or existing manufacturing/filling processes.